Marta Korbonits

List of Publications by Year in descending order

322 papers	19,098 citations	11651 70 h-index	16183 124 g-index
332 all docs	332 docs citations	332 times ranked	17396 citing authors

#	Article	IF	Citations
1	Epigenetic and postâ€transcriptional regulation of somatostatin receptor subtype 5 (SST₅) in pituitary and pancreatic neuroendocrine tumors. Molecular Oncology, 2022, 16, 764-779.	4.6	6
2	Treatment of congenital adrenal hyperplasia in children aged 0â€“3 years: a retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure. European Journal of Endocrinology, 2022, 186, 587-596.	3.7	7
3	Molecular genetic testing in the management of pituitary disease. Clinical Endocrinology, 2022, 97, 424-435.	2.4	18
4	Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1906-1919.	3.6	12
5	Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes. Journal of the Endocrine Society, 2022, 6, bvab190.	0.2	5
6	Glucose and lipid metabolism abnormalities in <scp>C</scp>ushing's syndrome. Journal of Neuroendocrinology, 2022, 34, .	2.6	24
7	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3313-e3320.	3.6	7
8	Biochemical discrepancies in the evaluation of the somatotroph axis: Elevated GH or IGF-1 levels do not always diagnose acromegaly. Growth Hormone and IGF Research, 2022, 64, 101467.	1.1	6
9	Ockhamâ€™s Razor for a Retinal Lesion and Acromegaly and Breaking the Vicious Circle. Journal of the Endocrine Society, 2022, 6, .	0.2	2
10	AIP variant causing familial prolactinoma. Pituitary, 2021, 24, 48-52.	2.9	9
11	Real-World Estimates of Adrenal Insufficiencyâ€“Related Adverse Events in Children With Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e192-e203.	3.6	20
12	Clinical Outcomes and Complications of Pituitary Blastoma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 351-363.	3.6	23
13	Pre-operative serum inflammation-based scores in patients with pituitary adenomas. Pituitary, 2021, 24, 334-350.	2.9	21
14	Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1183-e1194.	3.6	48
15	Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. Endocrine Connections, 2021, 10, 76-83.	1.9	12
16	Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research. Endocrine, 2021, 71, 561-568.	2.3	4
17	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.2	31
18	The clinical aspects of pituitary tumour genetics. Endocrine, 2021, 71, 663-674.	2.3	18

#	Article	IF	Citations
19	Genetics of Acromegaly and Gigantism. Journal of Clinical Medicine, 2021, 10, 1377.	2.4	21
20	Molecular characterization of DICER1-mutated pituitary blastoma. Acta Neuropathologica, 2021, 141, 929-944.	7.7	11
21	International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry. European Journal of Endocrinology, 2021, 184, 553-563.	3.7	21
22	Serum Inflammation-based Scores in Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3796-e3819.	3.6	19
23	Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence. Endocrine Connections, 2021, 10, 387-400.	1.9	4
24	GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	6
25	Cabergoline reduces 3-methoxytyramine in a SDHC patient with metastatic paraganglioma and prolactinoma. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	1
26	RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas. Oncogene, 2021, 40, 6354-6368.	5.9	11
27	Management of children and young people with idiopathic pituitary stalk thickening, central diabetes insipidus, or both: a national clinical practice consensus guideline. The Lancet Child and Adolescent Health, 2021, 5, 662-676.	5.6	21
28	Natriuretic Peptide Expression and Function in GH3 Somatolactotropes and Feline Somatotrope Pituitary Tumours. International Journal of Molecular Sciences, 2021, 22, 1076.	4.1	1
29	The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours. Journal of Neuroendocrinology, 2021, 33, e13052.	2.6	6
30	Sex-biased islet Î² cell dysfunction is caused by the MODY MAFA S64F variant by inducing premature aging and senescence in males. Cell Reports, 2021, 37, 109813.	6.4	27
31	Approach to the Patient with Pseudoacromegaly. Journal of Clinical Endocrinology and Metabolism, 2021, , .	3.6	2
32	Case Report: Malignant Primary Sellar Paraganglioma With Unusual Genetic and Imaging Features. Frontiers in Oncology, 2021, 11, 739255.	2.8	3
33	Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 314-326.	3.6	30
34	Acquired Ectopic Posterior Pituitary Bright Spot Due to Vasculotoxic Snakebite. AACE Clinical Case Reports, 2020, 6, e207-e211.	1.1	2
35	Update on the Genetics of Pituitary Tumors. Endocrinology and Metabolism Clinics of North America, 2020, 49, 433-452.	3.2	22
36	Unusual Combination of MEN-1 and the Contiguous Gene Deletion Syndrome of CAH and Ehlers-Danlos Syndrome (CAH-X). Journal of the Endocrine Society, 2020, 4, bvaa077.	0.2	1

#	Article	IF	Citations
37	The role of the tumour microenvironment in the angiogenesis of pituitary tumours. Endocrine, 2020, 70, 593-606.	2.3	22
38	The tumour microenvironment of pituitary neuroendocrine tumours. Frontiers in Neuroendocrinology, 2020, 58, 100852.	5.2	29
39	Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. Endocrine Reviews, 2020, 41, 821-846.	20.1	61
40	XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances, 2020, 6, eaba3231.	10.3	37
41	Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 278-291.	11.4	60
42	Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine, 2020, 67, 651-658.	2.3	19
43	Pachydermoperiostosis mimicking the acral abnormalities of acromegaly. Endocrine, 2020, 67, 499-500.	2.3	8
44	Phenotypic and genotypic features of a large kindred with a germline AIP variant. Clinical Endocrinology, 2020, 93, 146-153.	2.4	3
45	Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2247-e2260.	3.6	37
46	Identification of a TMEM127 variant in a patient with paraganglioma and acromegaly. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.5	4
47	Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutationâ€'Positive Child. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3539-3544.	3.6	41
48	Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathologica Communications, 2019, 7, 172.	5.2	65
49	Pediatric Parathyroid Carcinoma: A Case Report and Review of the Literature. Journal of the Endocrine Society, 2019, 3, 2224-2235.	0.2	15
50	Redefining the perioperative stress response: a narrative review. British Journal of Anaesthesia, 2019, 123, 570-583.	3.4	77
51	Clinical and Pathological Aspects of Silent Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2473-2489.	3.6	120
52	Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation. Cell Reports, 2019, 27, 1461-1471.e4.	6.4	17
53	Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene, 2019, 38, 5381-5395.	5.9	59
54	Phosphodiesterases and cAMP Pathway in Pituitary Diseases. Frontiers in Endocrinology, 2019, 10, 141.	3.5	5

#	Article	IF	Citations
55	Pseudoacromegaly. Frontiers in Neuroendocrinology, 2019, 52, 113-143.	5.2	23
56	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 213-220.	11.4	86
57	Pituitary Pathology and Gene Expression in Acromegalic Cats. Journal of the Endocrine Society, 2019, 3, 181-200.	0.2	17
58	Genetics of Pituitary Tumours. Experientia Supplementum (2012), 2019, 111, 171-211.	0.9	6
59	MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect?. Journal of the Endocrine Society, 2019, 3, .	0.2	3
60	Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion. Endocrine Connections, 2019, 8, 326-337.	1.9	3
61	The current landscape of European registries for rare endocrine conditions. European Journal of Endocrinology, 2019, 180, 89-98.	3.7	25
62	Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. Endocrine-Related Cancer, 2019, 26, 853-865.	3.1	35
63	Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects. Journal of Endocrinology, 2019, 240, R21-R45.	2.6	55
64	Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules. Endokrynologia Polska, 2019, 70, 213-217.	1.0	7
65	Assessment of Cardiavascular Changes following Trans-sphenoidal Surgery in Acromegalic Patients. Neurology India, 2019, 67, 1170.	0.4	0
66	MON-462 Cytokine Network in Pituitary Adenomas and Its Role in the Tumor Microenvironment: Focus on Macrophages. Journal of the Endocrine Society, 2019, 3, .	0.2	0
67	SAT-462 AIP Mutation-Positive Patients with Somatotropinomas End up Taller and Requiring Radiotherapy More Often Compared to AIP Mutation-Negative Patients: Data from 784 Familial and Young-Onset Cases. Journal of the Endocrine Society, 2019, 3, .	0.2	0
68	OR16-1 Best of The Journal of Clinical Endocrinology & Metabolism: Macimorelin as a Diagnostic Test for Adult GH Deficiency. Journal of the Endocrine Society, 2019, 3, .	0.2	0
69	Risk category system to identify pituitary adenoma patients with AIP mutations. Journal of Medical Genetics, 2018, 55, 254-260.	3.2	35
70	UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS. Endocrine Practice, 2018, 24, 473-488.	2.1	55
71	Metabolic Syndrome in Cushing's Syndrome Patients. Frontiers of Hormone Research, 2018, 49, 85-103.	1.0	42
72	In vivobioassay to test the pathogenicity of missense humanAIPvariants. Journal of Medical Genetics, 2018, 55, 522-529.	3.2	15

#	Article	IF	Citations
73	A novel <scp>DICER</scp>1 mutation in familial multinodular goitre. Clinical Endocrinology, 2018, 89, 110-112.	2.4	5
74	CantÃº syndrome with coexisting familial pituitary adenoma. Endocrine, 2018, 59, 677-684.	2.3	13
75	MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1027-1032.	7.1	88
76	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	3.7	196
77	Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas. Molecular and Cellular Endocrinology, 2018, 476, 103-109.	3.2	10
78	Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathologica, 2018, 135, 757-777.	7.7	106
79	International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacological Reviews, 2018, 70, 763-835.	16.0	163
80	Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland. Oncotarget, 2018, 9, 9177-9198.	1.8	31
81	Proteomic Analysis of the Human Anterior Pituitary Gland. OMICS A Journal of Integrative Biology, 2018, 22, 759-769.	2.0	23
82	Coexisting pituitary and nonâ€pituitary gigantism in the same family. Clinical Endocrinology, 2018, 89, 887-888.	2.4	4
83	Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome. Case Reports in Endocrinology, 2018, 2018, 1-6.	0.4	6
84	Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Membersâ€™ View in anAIPMutation-Positive Family. International Journal of Endocrinology, 2018, 2018, 1-15.	1.5	9
85	CRAN-40. A NATIONAL UK GUIDELINE FOR MANAGING PITUITARY ADENOMAS IN CHILDREN AND YOUNG PEOPLE UNDER 19 YEARS DEVELOPED ACCORDING TO THE AGREE II FRAMEWORK. Neuro-Oncology, 2018, 20, i44-i45.	1.2	1
86	Macimorelin as a Diagnostic Test for Adult GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3083-3093.	3.6	71
87	Unusual AIP mutation and phenocopy in the family of a young patient with acromegalic gigantism. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.5	3
88	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelsonâ€™s tumor. European Journal of Endocrinology, 2018, 178, 57-63.	3.7	37
89	Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas. Oncotarget, 2018, 9, 29180-29192.	1.8	7
90	A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.5	4

#	Article	IF	Citations
91	Metformin prevents metabolic side effects during systemic glucocorticoid treatment. European Journal of Endocrinology, 2017, 176, 349-358.	3.7	35
92	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocrine-Related Cancer, 2017, 24, C5-C8.	3.1	262
93	The genetic background of acromegaly. Pituitary, 2017, 20, 10-21.	2.9	65
94	Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 365-367.	1.2	7
95	A unique haplotype of RCCX copy number variation: from the clinics of congenital adrenal hyperplasia to evolutionary genetics. European Journal of Human Genetics, 2017, 25, 702-710.	2.8	10
96	Pachydermoperiostosis Masquerading as Acromegaly. Journal of the Endocrine Society, 2017, 1, 109-112.	0.2	10
97	PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex. European Journal of Endocrinology, 2017, 177, K7-K12.	3.7	36
98	Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. Expert Review of Endocrinology and Metabolism, 2017, 12, 143-153.	2.4	28
99	Genetic Aspects of Pituitary Adenomas. Endocrinology and Metabolism Clinics of North America, 2017, 46, 335-374.	3.2	47
100	Pituitary Carcinoma in a Patient with an SDHB Mutation. Endocrine Pathology, 2017, 28, 320-325.	9.0	50
101	Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas. Pathology and Oncology Research, 2017, 23, 633-641.	1.9	19
102	Social, educational and vocational outcomes in patients with childhoodâ€onset and youngâ€adultâ€onset growth hormone deficiency. Clinical Endocrinology, 2017, 86, 526-533.	2.4	6
103	AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation. Endocrine Connections, 2017, 6, 914-925.	1.9	18
104	AIP and the somatostatin system in pituitary tumours. Journal of Endocrinology, 2017, 235, R101-R116.	2.6	27
105	Pseudoacromegaly: A Differential Diagnostic Problem for Acromegaly With a Genetic Solution. Journal of the Endocrine Society, 2017, 1, 1104-1109.	0.2	14
106	In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. European Journal of Endocrinology, 2017, 177, 257-266.	3.7	12
107	Succinate Dehydrogenase B (SDHB)-Associated Bladder Paragangliomas. Clinical Genitourinary Cancer, 2017, 15, e131-e136.	1.9	9
108	Increased Population Risk ofAIP-Related Acromegaly and Gigantism in Ireland. Human Mutation, 2017, 38, 78-85.	2.5	25

#	Article	IF	Citations
109	Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. Clinical Endocrinology, 2017, 86, 286-296.	2.4	34
110	Fatal Carney Complex in Siblings Due to De Novo Large Gene Deletion. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3924-3927.	3.6	17
111	Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour. Endocrinology, Diabetes and Metabolism Case Reports, 2017, 2017, .	0.5	8
112	Genetics of pituitary adenomas. Neurology India, 2017, 65, 577.	0.4	17
113	Genetic Causes of Familial Pituitary Tumors. , 2017, , 185-211.		2
114	Echocardiographic improvements following transsphenoidal surgery for acromegaly. Neurology India, 2017, 65, 1225.	0.4	0
115	Novel Germline p.Gly42Val Mutation in a Family with Multiple Endocrine Neoplasia Type 1 - Excellent Response of Prolactinoma to Cabergoline. Annals of Clinical and Laboratory Science, 2017, 47, 606-610.	0.2	1
116	Diagnosis of Acromegaly. , 2016, , 223-229.		0
117	Clinical Features of Acromegaly. , 2016, , 212-222.		0
118	Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World Journal of Diabetes, 2016, 7, 572.	3.5	51
119	Clinicopathologic features of familial pituitary adenomas. Diagnostic Histopathology, 2016, 22, 85-91.	0.4	4
120	Pheochromocytoma Is Characterized byÂCatecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, andÂMyocardial Dysfunction. Journal of the American College of Cardiology, 2016, 67, 2364-2374.	2.8	139
121	AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience. Endocrine, 2016, 53, 402-411.	2.3	20
122	Gigantism: X-linked acrogigantism and GPR101 mutations. Growth Hormone and IGF Research, 2016, 30-31, 64-69.	1.1	20
123	Signaling network map of the aryl hydrocarbon receptor. Journal of Cell Communication and Signaling, 2016, 10, 341-346.	3.4	7
124	Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance. Endocrine, 2016, 54, 778-787.	2.3	15
125	Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathologica Communications, 2016, 4, 56.	5.2	110
126	Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With MissenseAIPMutations. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3144-3154.	3.6	47

#	Article	IF	Citations
127	Novel Genetic Causes of Pituitary Adenomas. Clinical Cancer Research, 2016, 22, 5030-5042.	7.0	107
128	cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors. Endocrine-Related Cancer, 2016, 23, 419-431.	3.1	29
129	SomaticGPR101Duplication Causing X-Linked Acrogigantism (XLAG)â€"Diagnosis and Management. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1927-1930.	3.6	48
130	Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. European Journal of Endocrinology, 2016, 174, 355-362.	3.7	56
131	Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. European Journal of Endocrinology, 2016, 174, 241-250.	3.7	122
132	Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma. Pituitary, 2016, 19, 50-56.	2.9	15
133	Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?. Neurology India, 2016, 64, 252.	0.4	19
134	Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1. International Journal of Pediatric Endocrinology (Springer), 2015, 2015, 15.	1.6	17
135	Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas. PLoS ONE, 2015, 10, e0117107.	2.5	59
136	Studying Cat (Felis catus) Diabetes: Beware of the Acromegalic Imposter. PLoS ONE, 2015, 10, e0127794.	2.5	51
137	Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. PLoS ONE, 2015, 10, e0143830.	2.5	16
138	Ghrelin. Molecular Metabolism, 2015, 4, 437-460.	6.5	810
139	15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocrine-Related Cancer, 2015, 22, T105-T122.	3.1	59
140	The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 481-487.	1.7	3
141	Prostatic hyperplasia in acromegaly, a myth or reality: a caseâ€"control study. European Journal of Endocrinology, 2015, 172, 97-106.	3.7	10
142	GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database. European Journal of Endocrinology, 2015, 172, 371-381.	3.7	55
143	Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: Impact of a multi-disciplinary team. Neurology India, 2015, 63, 360.	0.4	16
144	Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E531-E541.	3.6	145

#	Article	IF	Citations
145	Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1699-1708.	3.6	144
146	Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia. Endocrine, 2015, 50, 496-503.	2.3	5
147	Multi-parametric cardiovascular magnetic resonance imaging detects subclinical myocardial involvement in patients diagnosed with phaeochromocytoma. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P271.	3.3	0
148	Evaluation of genotypeâ€“phenotype relationships in patients referred for endocrine assessment in suspected Pendred syndrome. European Journal of Endocrinology, 2015, 172, 217-226.	3.7	15
149	The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E997-E1004.	3.6	163
150	Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis inAIPMutation Carriers. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1242-E1254.	3.6	144
151	The epidemiology of pituitary adenomas in Iceland, 1955â€“2012: a nationwide population-based study. European Journal of Endocrinology, 2015, 173, 655-664.	3.7	255
152	Metabolic comorbidities in Cushing's syndrome. European Journal of Endocrinology, 2015, 173, M133-M157.	3.7	128
153	An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140105.	0.5	9
154	Common Genetic Variants of the Human Steroid 21-Hydroxylase Gene (CYP21A2) Are Related to Differences in Circulating Hormone Levels. PLoS ONE, 2014, 9, e107244.	2.5	12
155	The role of ghrelin in weight-regulation disorders: Implications in clinical practice. Hormones, 2014, 13, 458-75.	1.9	21
156	Combination of 13-Cis Retinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice. Endocrinology, 2014, 155, 2377-2390.	2.8	15
157	Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas-kidney transplantation with systemic venous insulin delivery. Clinical Endocrinology, 2014, 80, 208-213.	2.4	8
158	Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. European Journal of Endocrinology, 2014, 171, 659-666.	3.7	46
159	Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. European Journal of Endocrinology, 2014, 171, 705-710.	3.7	12
160	Epidemiology and etiopathogenesis of pituitary adenomas. Journal of Neuro-Oncology, 2014, 117, 379-394.	2.9	181
161	Clinical Experience in the Screening and Management of a Large Kindred With Familial Isolated Pituitary Adenoma Due to an Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutation. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1122-1131.	3.6	53
162	Metforminâ€”mode of action and clinical implications for diabetes and cancer. Nature Reviews Endocrinology, 2014, 10, 143-156.	9.6	955

#	Article	IF	Citations
163	Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathologica, 2014, 128, 111-122.	7.7	211
164	Effects of smoking cessation on Î²-cell function, insulin sensitivity, body weight, and appetite. European Journal of Endocrinology, 2014, 170, 219-227.	3.7	67
165	Familial pituitary tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 124, 339-360.	1.8	21
166	Preface. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 124, ix.	1.8	0
167	Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2018-2029.	3.6	31
168	Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis. Endocrinology, Diabetes and Metabolism Case Reports, 2014, 2014, 140074.	0.5	13
169	Genetics of Pituitary Adenomas. Frontiers of Hormone Research, 2013, 41, 111-140.	1.0	61
170	The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. FASEB Journal, 2013, 27, 5112-5121.	0.5	25
171	Genetics of the Ghrelin System. Endocrine Development, 2013, 25, 25-40.	1.3	8
172	Novel pathway for somatostatin analogs in patients with acromegaly. Trends in Endocrinology and Metabolism, 2013, 24, 238-246.	7.1	126
173	ACTHâ€secreting Crooke cell carcinoma of the pituitary. European Journal of Clinical Investigation, 2013, 43, 20-26.	3.4	38
174	Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. Molecular and Cellular Endocrinology, 2013, 365, 303-308.	3.2	56
175	Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1918-E1926.	3.6	8
176	MicroRNAs: Suggested role in pituitary adenoma pathogenesis. Journal of Endocrinological Investigation, 2013, 36, 889-895.	3.3	29
177	A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. PLoS Genetics, 2013, 9, e1003350.	3.5	125
178	A Comprehensive Next Generation Sequencingâ€“Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1248-E1256.	3.6	92
179	CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. Journal of Endocrinology, 2013, 219, 79-88.	2.6	26
180	Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker. Stress, 2012, 15, 554-561.	1.8	10

#	Article	IF	Citations
181	Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. Journal of Molecular Endocrinology, 2012, 49, 79-96.	2.5	44
182	Expression of guanylyl cyclase-B (GC-B/NPR2) receptors in normal human fetal pituitaries and human pituitary adenomas implicates a role for C-type natriuretic peptide. Endocrine-Related Cancer, 2012, 19, 497-508.	3.1	13
183	Mice lacking AMP-activated protein kinase Î±1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment. Journal of Endocrinology, 2012, 214, 349-358.	2.6	22
184	Measurement of AMP-Activated Protein Kinase Activity and Expression in Response to Ghrelin. Methods in Enzymology, 2012, 514, 271-287.	1.0	12
185	Familial pituitary adenomas â€“ who should be tested for <scp>AIP</scp> mutations?. Clinical Endocrinology, 2012, 77, 351-356.	2.4	71
186	Familial isolated pituitary adenomas: An emerging clinical entity. Journal of Endocrinological Investigation, 2012, 35, 1003-1014.	3.3	21
187	Ghrelin Regulation of AMPK in the Hypothalamus and Peripheral Tissues. , 2012, , 91-110.		0
188	Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal Î±-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition. PLoS ONE, 2012, 7, e53339.	2.5	67
189	Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma. Arquivos Brasileiros De Endocrinologia E Metabologia, 2012, 56, 507-512.	1.3	17
190	Oncogene-induced senescence in pituitary adenomas and carcinomas. Hormones, 2012, 11, 297-307.	1.9	31
191	Pathogenesis of vascular complications in Cushingâ€™s syndrome. Hormones, 2012, 11, 21-30.	1.9	40
192	MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E708-E719.	3.5	71
193	Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Human Mutation, 2012, 33, 1175-1181.	2.5	74
194	Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1411-E1420.	3.6	122
195	Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor. Pituitary, 2012, 15, 61-67.	2.9	19
196	Paediatric endocrine aspects of ghrelin. Pediatric Endocrinology Reviews, 2012, 9, 628-38.	1.2	3
197	Ghrelin in obesity and endocrine diseases. Molecular and Cellular Endocrinology, 2011, 340, 15-25.	3.2	49
198	Genetic studies on the ghrelin, growth hormone secretagogue receptor (GHSR) and ghrelin O-acyl transferase (GOAT) genes. Peptides, 2011, 32, 2191-2207.	2.4	38

#	Article	IF	Citations
199	The Immunophilin-Like Protein XAP2 Is a Negative Regulator of Estrogen Signaling through Interaction with Estrogen Receptor Î±. PLoS ONE, 2011, 6, e25201.	2.5	21
200	The expression of ghrelin O-acyltransferase (GOAT) in human tissues. Endocrine Journal, 2011, 58, 707-710.	1.6	79
201	Specific electrocardiographic features associated with Cushingâ€™s disease. Clinical Endocrinology, 2011, 74, 558-564.	2.4	17
202	MicroRNA profile indicates downregulation of the TGFÎ² pathway in sporadic non-functioning pituitary adenomas. Pituitary, 2011, 14, 112-124.	2.9	106
203	The ghrelin/GOAT/GHS-R system and energy metabolism. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 173-186.	5.7	56
204	AIPMutation in Pituitary Adenomas in the 18th Century and Today. New England Journal of Medicine, 2011, 364, 43-50.	27.0	151
205	AIP and its interacting partners. Journal of Endocrinology, 2011, 210, 137-155.	2.6	124
206	MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine, 2010, 38, 67-75.	2.3	83
207	Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues. Endocrine Pathology, 2010, 21, 25-31.	9.0	12
208	Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. Biochemical Pharmacology, 2010, 80, 1736-1745.	4.4	63
209	Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Human Mutation, 2010, 31, 950-960.	2.5	154
210	Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 698-704.	1.3	23
211	Down-Regulation of Wee1 Kinase by a Specific Subset of microRNA in Human Sporadic Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E181-E191.	3.6	89
212	Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma. Expert Review of Endocrinology and Metabolism, 2010, 5, 681-695.	2.4	11
213	Molecular Genetics of the Aip Gene in Familial Pituitary Tumorigenesis. Progress in Brain Research, 2010, 182, 229-253.	1.4	17
214	Alterations in Adipose Tissue during Critical Illness. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 507-516.	5.6	60
215	Cyclins and their related proteins in pituitary tumourigenesis. Molecular and Cellular Endocrinology, 2010, 326, 25-29.	3.2	18
216	AIP gene and familial isolated pituitary adenomas. Molecular and Cellular Endocrinology, 2010, 326, 71-79.	3.2	46

#	Article	IF	Citations
217	AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone, 2010, 47, 309-319.	2.9	160
218	Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends in Endocrinology and Metabolism, 2010, 21, 419-427.	7.1	97
219	Ghrelinâ€™s Role as a Major Regulator of Appetite and Its Other Functions in Neuroendocrinology. Progress in Brain Research, 2010, 182, 189-205.	1.4	27
220	AMPK as a mediator of hormonal signalling. Journal of Molecular Endocrinology, 2010, 44, 87-97.	2.5	267
221	Regulation of Growth Hormone and Action (Secretagogues). , 2010, , 412-453.		1
222	Down-Regulation of Wee1 Kinase by a Specific Subset of microRNAs in Human Sporadic Pituitary Adenomas. Molecular Endocrinology, 2010, 24, 1886-1886.	3.7	0
223	Recent Clinical and Pathophysiological Advances in Non-Functioning Pituitary Adenomas. Hormone Research in Paediatrics, 2009, 71, 123-130.	1.8	34
224	Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocrine-Related Cancer, 2009, 16, 1329-1338.	3.1	129
225	Shedding light on the intricate puzzle of ghrelin's effects on appetite regulation. Journal of Endocrinology, 2009, 202, 191-198.	2.6	42
226	The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes. European Journal of Endocrinology, 2009, 161, 307-315.	3.7	34
227	Assessment of p27 (cyclinâ€dependent kinase inhibitor 1B) and aryl hydrocarbon receptorâ€interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clinical Endocrinology, 2009, 70, 259-264.	2.4	60
228	Association Studies on Ghrelin and Ghrelin Receptor Gene Polymorphisms With Obesity. Obesity, 2009, 17, 745-754.	3.0	60
229	A Genetic Study of the Ghrelin and Growth Hormone Secretagogue Receptor (GHSR) Genes and Stature. Annals of Human Genetics, 2009, 73, 1-9.	0.8	18
230	Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. European Journal of Endocrinology, 2009, 161, 655-662.	3.7	42
231	A new variation in the promoter region, the â^'604 C>T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance. International Journal of Obesity, 2008, 32, 663-668.	3.4	37
232	Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line. Neuroendocrinology, 2008, 87, 168-181.	2.5	114
233	The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2390-2401.	3.6	273
234	AMPâ€activated protein kinase mediates glucocorticoidâ€induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB Journal, 2008, 22, 1672-1683.	0.5	148

#	Article	IF	Citations
235	The role of somatostatin analogues in the treatment of neuroendocrine tumours. Molecular and Cellular Endocrinology, 2008, 286, 238-250.	3.2	47
236	Protein western array analysis in human pituitary tumours: insights and limitations. Endocrine-Related Cancer, 2008, 15, 1099-1114.	3.1	22
237	The potential role of D2 dopamine receptors as a target in the management of neuroendocrine tumors. Cancer Biology and Therapy, 2008, 7, 1979-1981.	3.4	1
238	The Role of AMP-Activated Protein Kinase in Obesity. , 2008, 36, 198-211.		85
239	Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocrine-Related Cancer, 2008, 15, 701-720.	3.1	145
240	HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients. Nephrology Dialysis Transplantation, 2008, 23, 2673-2678.	0.7	12
241	Changes in Adenosine 5â€²-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4969-4973.	3.6	76
242	Ghrelin Receptor Gene Polymorphisms and Body Size in Children and Adults. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4158-4161.	3.6	21
243	The Yin and Yang of the Ghrelin Gene Products. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2008, 8, 292-302.	0.5	2
244	The Orexigenic Effect of Ghrelin Is Mediated through Central Activation of the Endogenous Cannabinoid System. PLoS ONE, 2008, 3, e1797.	2.5	264
245	Obesity and Metabolism. Frontiers of Hormone Research, 2008, 36, ix.	1.0	4
246	Appetite and Metabolic Effects of Ghrelin and Cannabinoids: Involvement of AMP-Activated Protein Kinase. Vitamins and Hormones, 2007, 77, 121-148.	1.7	27
247	Metabolic and hormonal changes during the refeeding period of prolonged fasting. European Journal of Endocrinology, 2007, 157, 157-166.	3.7	73
248	Ghrelin, the peripheral hunger hormone. Annals of Medicine, 2007, 39, 116-136.	3.8	127
249	Examining the Candidacy of Ghrelin as a Gene Responsible for Variation in Adult Stature in a United Kingdom Population with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2201-2204.	3.6	7
250	A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clinical Endocrinology, 2007, 66, 348-352.	2.4	63
251	Ghrelin in neuroendocrine organs and tumours. Pituitary, 2007, 10, 213-225.	2.9	37
252	Ghrelin and cardiovascular health. Current Opinion in Pharmacology, 2006, 6, 142-147.	3.5	57

#	Article	IF	Citations
253	Expanding role of AMPK in endocrinology. Trends in Endocrinology and Metabolism, 2006, 17, 205-215.	7.1	190
254	PPARâ€Î³ expression in pituitary tumours and the functional activity of the glitazones: evidence that any antiâ€proliferative effect of the glitazones is independent of the PPARâ€Î³ receptor. Clinical Endocrinology, 2006, 65, 389-395.	2.4	37
255	Macro- and micronutrient losses and nutritional status resulting from 44 days of total fasting in a non-obese man. Nutrition, 2006, 22, 889-897.	2.4	27
256	Effect of Gastric Bypass and Gastric Banding on Proneurotensin Levels in Morbidly Obese Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3544-3547.	3.6	46
257	The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase Expression. Cancer Research, 2006, 66, 10120-10126.	0.9	157
258	Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. European Journal of Endocrinology, 2006, 155, 371-379.	3.7	100
259	A HIF1Î± Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics, 2005, 1, e8.	3.5	394
260	Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocrine-Related Cancer, 2005, 12, 423-433.	3.1	117
261	Differential gene expression in pituitary adenomas by oligonucleotide array analysis. European Journal of Endocrinology, 2005, 153, 143-151.	3.7	113
262	Refeeding David Blaine â€" Studies after a 44-Day Fast. New England Journal of Medicine, 2005, 353, 2306-2307.	27.0	23
263	Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase. Journal of Biological Chemistry, 2005, 280, 25196-25201.	3.4	425
264	Theobromine inhibits sensory nerve activation and cough. FASEB Journal, 2005, 19, 1-16.	0.5	98
265	Fasting and Postprandial Hyperghrelinemia in Prader-Willi Syndrome Is Partially Explained by Hypoinsulinemia, and Is Not Due to Peptide YY3â€"36Deficiency or Seen in Hypothalamic Obesity Due to Craniopharyngioma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2681-2690.	3.6	108
266	Non-Growth Hormone Endocrine Actions of Ghrelin. , 2004, , 73-89.		0
267	Elevated Fasting Plasma Ghrelin in Prader-Willi Syndrome Adults Is Not Solely Explained by Their Reduced Visceral Adiposity and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1718-1726.	3.6	107
268	Ghrelin: update on a novel hormonal system. European Journal of Endocrinology, 2004, 151 Suppl 1, S67-S70.	3.7	63
269	Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. European Journal of Endocrinology, 2004, 151, 233-240.	3.7	121
270	Akting and Cycling: A Tale of the Pituitary. Hormone Research in Paediatrics, 2004, 62, 117-123.	1.8	7

#	Article	IF	Citations
271	A Comparison of a Novel Testosterone Bioadhesive Buccal System, Striant, with a Testosterone Adhesive Patch in Hypogonadal Males. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2039-2043.	3.6	64
272	Striantâ„¢ SR: a novel, effective and convenient testosterone therapy for male hypogonadism. International Journal of Clinical Practice, 2004, 58, 1073-1080.	1.7	18
273	The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. British Journal of Pharmacology, 2004, 143, 520-523.	5.4	162
274	Ghrelin?a hormone with multiple functions. Frontiers in Neuroendocrinology, 2004, 25, 27-68.	5.2	496
275	Cell Cycle Dysregulation in Pituitary Oncogenesis. , 2004, 32, 34-62.		58
276	Role of Regulatory Factors in Pituitary Tumour Formation. , 2004, 32, 63-95.		19
277	Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clinical Endocrinology, 2003, 58, 572-580.	2.4	19
278	Reduced expression of the growth hormone and type 1 insulinâ€like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clinical Endocrinology, 2003, 59, 328-338.	2.4	37
279	Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro. Journal of Endocrinological Investigation, 2003, 26, 743-747.	3.3	21
280	Identification of Adrenocorticotropin Receptor Messenger Ribonucleic Acid in the Human Pituitary and Its Loss of Expression in Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 6080-6087.	3.6	43
281	Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. Journal of Endocrinology, 2003, 176, 103-110.	2.6	35
282	Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. Journal of Endocrinology, 2003, 178, 301-310.	2.6	21
283	The KrâˆšÂºppel-like transcription factor 6 gene in sporadic pituitary tumours.. Endocrine-Related Cancer, 2003, 10, 397-402.	3.1	12
284	Ghrelin is Released from Rat Hypothalamic Explants and Stimulates Corticotrophin-releasing Hormone and Arginine-vasopressin. Hormone and Metabolic Research, 2003, 35, 455-459.	1.5	117
285	The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2988-2991.	3.6	1,082
286	A Variation in the Ghrelin Gene Increases Weight and Decreases Insulin Secretion in Tall, Obese Children. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4005-4008.	3.6	141
287	Expression of Phosphorylated p27^{Kip1}Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2635-2643.	3.6	102
288	Cell Cycle Dysregulation in Human Pituitary Tumours. Clinical Science, 2002, 103, 22P-22P.	0.0	0

#	Article	IF	Citations
289	Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clinical Endocrinology, 2002, 57, 443-448.	2.4	72
290	The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors. Pituitary, 2002, 5, 235-242.	2.9	16
291	Optimal Response Criteria for the Human CRH Test in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1640-1645.	3.6	76
292	Response of Serum Macrophage Migration Inhibitory Factor Levels to Stimulation or Suppression of the Hypothalamo-Pituitary-Adrenal Axis in Normal Subjects and Patients with Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1834-1840.	3.6	23
293	The release of leptin and its effect on hormone release from human pituitary adenomas. Clinical Endocrinology, 2001, 54, 781-789.	2.4	36
294	Leptin and puberty: a review. Pituitary, 2001, 4, 79-86.	2.9	40
295	Presence of Ghrelin in Normal and Adenomatous Human Pituitary. Endocrine, 2001, 14, 101-104.	2.2	115
296	Imprinting of the GsÎ± gene GNAS1 in the pathogenesis of acromegaly. Journal of Clinical Investigation, 2001, 107, R31-R36.	8.2	266
297	The Expression of the Growth Hormone Secretagogue Receptor Ligand Ghrelin in Normal and Abnormal Human Pituitary and Other Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 881-887.	3.6	210
298	Expression of 11Â-Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2728-2733.	3.6	52
299	How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?. Clinical Endocrinology, 2000, 53, 493-500.	2.4	91
300	Expression of the Pituitary Transcription Factor Ptx-1, But Not That of the Trans-Activating Factor Prop-1, Is Reduced in Human Corticotroph Adenomas and Is Associated with Decreased Â-Subunit Secretion. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2537-2542.	3.6	10
301	The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2489-2495.	3.6	96
302	Expression of menin gene mRNA in pituitary tumours. European Journal of Endocrinology, 1999, 140, 358-361.	3.7	29
303	Hexarelin as a test of pituitary reserve in patients with pituitary disease. Clinical Endocrinology, 1999, 51, 369-375.	2.4	21
304	The Effect of Growth Hormone Secretagogues and Neuropeptide Y on Hypothalamic Hormone Release from Acute Rat Hypothalamic Explants. Journal of Neuroendocrinology, 1999, 11, 521-528.	2.6	73
305	The Effects of GH-Secretagogues on Human Pituitary Cells in Culture and on Rat Hypothalamic Tissue. , 1999, , 65-77.		2
306	Leptin and the thyroid - A puzzle with missing pieces. Clinical Endocrinology, 1998, 49, 569-572.	2.4	28

#	Article	IF	Citations
307	Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3624-3630.	3.6	75
308	Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3624-3630.	3.6	64
309	Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitaryâ€adrenal activity. Clinical Endocrinology, 1997, 46, 751-757.	2.4	128
310	Differential stimulation of corticol and dehydropiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. Clinical Endocrinology, 1996, 45, 699-706.	2.4	53
311	l-Arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide. European Journal of Endocrinology, 1996, 135, 543-547.	3.7	26
312	The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Clinical Endocrinology, 1995, 43, 365-371.	2.4	52
313	Growth hormone-releasing peptide and its analogues. Trends in Endocrinology and Metabolism, 1995, 6, 43-49.	7.1	115
314	Determination of Direct Effects of Cytokines on Release of Neuropeptides from Rat Hypothalamus by an in Vitro Method. Methods in Neurosciences, 1993, 16, 302-326.	0.5	1
315	Glioma in an AIP mutation carrier patient. Endocrine Abstracts, 0, , .	0.0	1
316	Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma. Endocrine Abstracts, 0, , .	0.0	2
317	Changes in pituitary tumour biology and behaviour in FIPA patient with GH secreting aggressive pituitary macro adenoma. Endocrine Abstracts, 0, , .	0.0	2
318	Investigating the role of AIP in mouse pituitary adenoma formation. Endocrine Abstracts, 0, , .	0.0	3
319	Identifying disease causing variants in aryl hydrocarbon receptor-interacting protein (AIP) variants and their significance on the clinical phenotypes. Endocrine Abstracts, 0, , .	0.0	1
320	Investigating the role of AIP in pituitary tumourigenesis. Endocrine Abstracts, 0, , .	0.0	1
321	Unusual cause of gigantism - Growth hormone releasing hormone (GHRH)-secreting pancreatic neuroendocrine tumour in a patient with multiple endocrine neoplasia type 1 (MEN1). Endocrine Abstracts, 0, , .	0.0	1
322	Phenotypic differences between patients with familial pituitary neuroendocrine tumours due to MEN1 or AIP mutations. Endocrine Abstracts, 0, , .	0.0	1